IntelGenx announced that it has received the first purchase order, PO, for RIZAFILM1 from its commercial partner in the United States, Gensco Pharma. The PO triggers an upfront order deposit payment. A pre-specified milestone payment to IntelGenx from Gensco is also payable upon transfer of NDA. Both payments will be reflected in the Company’s Q3-2023 financial results. IntelGenx expects to ship the ordered RIZAFILM product to Gensco in Q1-2024 for immediate launch. “We have been impressed with the progress Gensco has made, and remain convinced that it is the right partner to help us bring this innovative migraine therapeutic to U.S. patients seeking convenient administration and quick pain relief,” commented Dwight Gorham, IntelGenx’s CEO. “We are also pleased that our balance sheet will be strengthened in the current quarter by the deposit and milestone payments triggered by Gensco’s PO for RIZAFILM.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IGXT:
- IntelGenx Provides RIZAFILM® U.S. Commercialization Update
- IntelGenx Announces Closing of First Tranche of Non-Brokered Private Placement From Strategic Partner for Approximate Aggregate Gross Proceeds of US$3 Million (Including US$750,000 to be Received by the Company Once Shareholder Approvals Have Been Obtained)
- IntelGenx Reports Second Quarter 2023 Financial Results
- IntelGenx Announces First Agreement for CDMO Packaging Services
- IntelGenx to Report Second Quarter 2023 Financial Results on August 14, 2023 – Conference Call to Follow